New Allogeneic T-Cell Therapy Receives Rare Pediatric Disease Designation for Congenital CMV Infection

The FDA granted rare pediatric disease designation to ATA230, an allogeneic T-cell therapy, for the treatment of congenital cytomegalovirus (CMV) infection. ATA230 targets antigens expressed by CMV and is being investigated in phase I and II clinical trials of patients with CMV viremia or disease that is refractory or resistant to antiviral drug treatment in the post-transplant setting.

Source: Altara Biotherapeutics, Inc., press release, October 26, 2017.

SHARE